Amarin Corp Plc (AMRN)

[ziploc_1]

Vascepa has an exclusive for many years in Europe (where there is no gV)...Amarin can attain high volumes of Vascepa sales in U.S through lower prices with an AG.... combined with their sales in Europe, where there is no gV....thus Amarin can afford to lower their prices even further in the U.S. and around the world in order to enhance these volumes, thereby surpassing the volumes of gV in the U.S....These lower prices and enhanced volumes for Amarin will lead to lower costs to Amarin for their API...and can make the lower priced Vascepa profitable for Amarin, while making gV less profitable for gV companies, who will have to pay more for API their own gV product.

John Thero said years ago..."Vascepa is a volume play...not a price play." Now is the time to enact his idea.

We know Vascepa is the right product...Perhaps it is just the price, which is wrong!